LONDON (AFX) - Merck & Co Inc has acquired the worldwide rights to Ambrilia Biopharma Inc's HIV/AIDS protease inhibitor programme for 17 mln usd plus milestone payments of up to 215 mln usd, the two companies said. newsdesk@afxnews.com har COPYRIGHT Copyright AFX News Limited 2006. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
© 2006 AFX News
